Диссертация (1140170), страница 16
Текст из файла (страница 16)
Клиническое значение удлиненияинтервалов QT и QTc на фоне приема лекарственных препаратов. Рациональнаяфармакотерапия в кардиологии 2013;9(3):311-315.45.Черемисина А.Ю., Анциферова Е.В., Воронина Н.А., СтельмашукТ.В., Емельянчик Е.Ю., Никулина С.Ю. Проблемы диагностики синдромаудлиненного интервала QT у новорожденных детей. // Лечащий врач. 2016.-N 7.С.58-60. Библ. 10 назв46.Чернова А.Л. Cиндром удлиненного интервала QT. // Сибирскоемедицинское обозрение. 2012.-N 3.-С.91-95. Библ. 30 назв.47.Шилов А. М., Мельник М.
В. Синдром удлиненного интервала QT какпредиктор сложных нарушений сердечного ритма и внезапной смерти. – 2005.11248.Ших Е.В., Фомин Е.В., Шумянцева В.В., Булко Т.В. Комбинированнаятерапия пожилых пациентов с учетом метаболизма лекарственных средств. //Клиническая геронтология. 2012.-N 3-4.-С.54-58. Библ. 13 назв.49.Школьникова М.А., Березницкая В.В., Калинин Л.А., Ильдарова Р.А.,Харлап М.С. Диагностика, стратификация риска внезапной смерти и лечениеосновныхмолекулярно-генетическихвариантовсиндромаудлиненногоинтервала. // Кардиология. 2011.-N 5.-С.50-61.
Библ. 48 назв.50.Abbott, G., Sesti, F., Splawski, I., Buck, M., Lehmann, M., Timothy, K. etal. (1999) MiRP1 forms IKR potassium channels with hERG and is associated withcardiac arrhythmia. Cell 97: 175-187.51.Abdelmawla N and Mitchel AJ. Sudden cardiac death and antipsychoticsdrugs. // Advances in Psychiatric Treatment 2006;12:35-44;100-109.52.Aberg K, Adkins DE, Liu Y, McClay JL, Bukszar J, Jia P, et al. Genome-wide association study of antipsychotic-inducedQTc intervalprolongation.Pharmacogenomics J. 2012;12(2):165–72.53.Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Druginteractions of clinical significance.
Drug Saf 1998;18:83-97.54.Alesso,L.,Colombo,H.,Torre,M.andHerrera, R.(2009)Amiodarone/ciprofloxacin/clarithromycin interaction. Prolonged QT interval andventricular tachycardia in an elderly patient: case report. Reactions Weekly 1272(Issue1, October): 6-7.55.Allan EL, Barker KN, Malloy MJ, Heller WM. Dispensing errors andcounseling in community practice.
Am Pharm 1995;35:25-33.56.JH,etAllen LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, Gurwitzal.Frequencyofhigh-riskuseofQT-prolongingmedications.Pharmacoepidemiol Drug Saf. 2006;15:361–8.57.Alvarez-ElcoroS,EnzlerMJ.Themacrolides:clarithromycin, and azithromycin.
Mayo Clin Proc 1999;74:613-34.113erythromycin,58.Anon. Seldane® withdrawal requested by FDA because "unique molecule"status has ended, agency says; Hoechst declares intent to fight withdrawal via hearingprocess. F-D-C Reports. 1997;59(3):11-2.59.Baker B, Dorian P, Sandor P, Shapiro C, Mitchell J, Irvine MJ.Electrocardiographic effects of fluoxetine and doxepin in patients with major depressivedisorders.
J Clin Psychopharmacol 1997;17:15-21.60.Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of thenewer fluoroquinolone antibacterials. Drug Saf 1999;21:407-21.61.Ball P. New antibiotics for community-acquired lower respiratory tractinfections: improved activity at a cost? International Journal of Antimicrobial Agents2000;16:263-72.62.Ball P. Quinolone induced QT interval prolongation: a not unexpected classeffect. J Antimicrob Chemother 2000;45:557-9.63.Barnett AA.
Safety concerns over antipsychotic drug, sertindole. Lancet1996;348:256.64.Beach S. R. et al. QTc prolongation, torsades de pointes, and psychotropicmedications //Psychosomatics. – 2013. – Т. 54. – №. 1. – С. 1-13.65.Bednar, M., Harrigan, E., Anziano, R., Camm, A. and Ruskin, J. (2001)The QT interval. Prog Cardiovasc Dis 43(5 Suppl.
1): 1-45.66.Border W.L., Benson D.W. Sudden infant death syndrome and long QTsyndrome: the zealots versus the naysayers. Heart Rhythm. 2007;4 (2): 167–9.67.Bril, F., Gonzalez, C. and Di Girolamo, G. (2010) Antimicrobial agents-associated with QT interval prolongation. Curr Drug Safety 5: 85-92.68.Brown S.
Excess mortality of schizophrenia, a metaanalysis.// Br JPsychiatry 1997;171:502-508.69.Brugada J, Brugada R, Brugada P. Pharmacological and device approach totherapy of inherited cardiac diseases associated with cardiac arrhythmias and suddendeath. J Electrocardiol 2000; 33 Suppl: 41-47.11470.Buchanan Keller, K. and Lemberg, L. (2008) ‘‘Torsade’’. Am J Crit Care17: 77-81.71.Buckley N, Sanders P.
Cardiovascular adverse effects of antipsychoticdrugs // Drug Safety 2000;23(3):215-22.72.Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common inthioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995;33:199204.73.Cetin, M., Yildirimer, M., Ozen, S., Tanriverdi, S. and Coskun, S. (2012)Clarithromycin-induced long QT syndrome: a case report. Case Rep Med 2012: 634652.74.Chen L., Marquardt M.L., Tester D.J. et al. Mutation of an A-kinase-anchoring protein causes long-QT syndrome // Proc. Natl. Acad. Sci.
USA. - 2007. Vol. 104. - P. 20990-20995.75.Chiang C.E., Roden D.M. The long QT syndromes: genetic basis andclinical implications. JACC. 2000; 36 (1): 1–12.76.Choudhury, L., Grais, I. and Passman, R. (1999) Torsades de pointes due todrug interaction between disopyramide and clarithromycin. Heart Disease (Hagerstown,MD) 1: 206-207.77.Combined List of Drugs that Prolong QT and/or cause Torsades de Pointes(TdP). [Электронный ресурс] // Режим доступа: https://www.crediblemeds.org.78.Committee on Safety of Medicines-Medicines Control Agency.
Cardiacarrhythmias with pimozide (Orap). Current Problems in Pharmacovigilance 1995;21:1.79.Committee on Safety of Medicines-Medicines Control Agency. Suspensionof availability of sertindole (serdolect). Current Problems in Pharmacovigilance1999;25:1.80.Conder ML, Lawrence JH, Levesque PC, Blanar MA. Inhibition of theHERG potassium ion channel by fluoroquinolone antibiotics: correlation with the riskfor clinically significant QT interval prolongation [abstr]. In: Program and abstracts ofthe 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto,115Ontario, Canada, September 17-20, 2000.
Washington, DC: American Society forMicrobiology, 2000:474.81.Crumb WJ Jr, Ekins S, Sarazan RD, Wikel JH, Wrighton SA, Carlson C, etal. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QTprolongation, structure activity relationship, and network analysis. Pharm Res.2006;23(6):1133–43.82.Curtis, L., Ostbye, T., Sendersky, V., Hutchison, S., Allen Lapointe, N.,Al-Khatib, S. et al. (2003) Prescription of QT-prolonging drugs in a cohort of about 5million outpatients. Am J Med 114: 135-141.83.Davey P.
QT interval and mortality from coronary artery disease. ProgCardiovasc Dis 2000 Mar Apr, 42(5):359-384.84.Delpon E, Valenzuela C, Tamargo J. Blockade of cardiac potassium andother channels by antihistamines. Drug Saf 1999;21(Suppl 1):11-8.85.Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y, et al.Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor andextensive metabolizers of CYP2D6. Pharmacogenomics J.
2003;3(2):105–13.86.Drici MD, Barhanin J. Cardiac K+ channels and drug-acquired long QTsyndrome. Therapie. 2000;55(1):185–93.87.Drug Interactions Checker. Электронный ресурс удаленного доступа –(http://www.drug.com).88.DuBuske LM. Second-generation antihistamines: the risk of ventriculararrhythmias. Clin Ther 1999;21:281-95.89.Duncan, R., Ridley, J., Dempsey, C., Leishman, D., Leaney, J., Hancox, J.et al. (2006) Erythromycin block of the hERG Kþ channel: accessibility to F656 andY652.
Biochem Biophys Res Commun 341: 500-506.90.FDA issues public health advisory for antipsychotic drugs used fortreatment of behavioral disorders in elderly patients (FDA talk Paper) Rochvill (MD):US Food and Drug Adminstration,2006.11691.Federal Drug Commission. FDA/PhRMA task force to assess QT risk bypre-clinical markers. Pink Sheet 1999;61:15-16.92.Ficker E., Dennis A.T., Obejero-Paz C.A. et al. Retention in theendoplasmic reticulum as a mechanism of dominant-negative current suppression inhuman long QT syndrome. J Mol Cell Cardiol 2000 Dec;32(12): 2327-2337.93.Finlayson K, Witchel HJ, McCulloch J, Sharkey J.
Acquired QT intervalprolongation and HERG: implications for drug discovery and development. Eur JPharmacol. 2004;500(1–3):129–42.94.Flockhart DA. Drug interactions, cardiac toxicity, and terfenadine: frombench to clinic? J Clin Psychopharmacol 1996;16:101-3.95.Geelen J., Doevendans P., Jongbloed R. et al. Molecular genetics ofinherited long QT syndromes. Eur Heart J 1998; 19: 1427-1433.96.Georgijevic Milic L. Molecular genetics in the hereditary form of long QTsyndrome. Med Pregl 2000 Jan-Feb; 53(1-2): 51-54.97.Glaxo Wellcome Inc.
Product information: Raxar (grepafloxacin).Research Triangle Park, NC;1997.98.Goldenberg I., Moss A.J. et al. Clinical course and risk stratification ofpatients affected with the Jervell and Lange-Nielsen syndrome. J CardiovascElectrophysiol. Nov 2006;17(11):1161-899.Goldenberg I., Moss A.J. Long QT syndrome. JACC. 2008; 51 (24): 2291–300.100. Gray, V. (1998) Syncopal episodes associated with cisapride andconcurrent drugs. Ann Pharmacother 32: 648-651.101. Guo D,Cai Y,Chai D,Liang B,Bai N,Wang R.The cardiotoxicity ofmacrolides:a systematic review.Pharmazie 2010;65:631–40.102. Gury C, Canceil O, Iaria P.
[Antipsychotic drugs and cardiovascular safety:current studies of prolonged QT interval and risk of ventricular arrhythmia]. Encephale2000;26:62-72.117103. Hancox, J., McPate, M., El Harchi, A. and Zhang, Y. (2008) The hERGpotassium channel and hERG screening for drug-induced torsades de pointes.Pharmacol Therapeut 119: 118-132.104. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR,Antzelevitch C, et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
